A venture backed medical device company, is investigating minimally invasive technology intended to transform the treatment of mitral regurgitation. The company has an exclusive worldwide license to the technology and is currently working on additional minimally invasive technologies for the treatment of structural heart disease.
NeoChord Crosses 250th Patient Milestone!
June 30, 2015
NeoChord conducted a live case at CSI Congress 2015 in Frankfurt, Germany;
June 27, 2015
NeoChord Secures $20 Million Series C Financing;
June 9, 2015
- Click for Release -
"NeoChord is setting a new standard for minimally invasive mitral valve repair, and at our institution has become the first-line treatment option for degenerative mitral valve regurgitation."
-Professor Gino Gerosa, University of Padova Medical School, Italy.